Stockscreener 앱 받기
732.58
0.08%
0.62
시간 외 거래:
730.75
-1.83
-0.25%
Lilly Eli Co 주식(LLY)의 최신 뉴스
Can trapped investors hope for a rebound in Eli Lilly and CompanyTrade Performance Summary & Detailed Earnings Play Alerts - Newser
Eli Lilly’s SWOT analysis: stock’s growth potential in obesity market faces challenges - Investing.com
Eli Lilly (LLY) Partners with JD.com to Sell Weight-Loss Drugs in China - TipRanks
ESC25: Novo's Wegovy slashes CV risk by 57% over Lilly's Zepbound in real-world study - FirstWord Pharma
Can you recover from losses in Eli Lilly and CompanyJuly 2025 Levels & Verified Chart Pattern Trade Signals - Newser
HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700 - Yahoo Finance
Intraday pattern recognizer results for Eli Lilly and CompanyPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks - inkl
Eli Lilly is close to launching the strongest weight-loss drug ever. Somehow, gym bros are already taking it to shred fat. - Business Insider
Eli Lilly and Company (LLY): A Bull Case Theory - MSN
Sector ETF performance correlation with Eli Lilly and Company2025 Geopolitical Influence & Consistent Profit Trading Strategies - Newser
Eli Lilly and Company (LLY) Needs To Get A Weight Loss Pill Out, Says Jim Cramer - Yahoo Finance
Pharmaceutical Cos. Back Lilly In Mich. Insulin Pricing Probe - Law360
Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill - Yahoo Finance
The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies - ca.finance.yahoo.com
Eli Lilly (NYSE:LLY) vs Novo Nordisk (NYSE:NVO): Growth Premium vs Value Upside - tradingnews.com
Eli Lilly (NYSE:LLY) Stock Price Trading at $732 as GLP-1 Sales Surge and Drug Pricing Risks Rise - tradingnews.com
Lilly Is Angling For Approval Of Its Obesity Pill. Is It Now A Buy? - Investor's Business Daily
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy - Benzinga
Eli Lilly Temporarily Stops U.K. Shipments of Its Weight-Loss Drug - TipRanks
Eli Lilly Partners with JD Health for Direct-to-Consumer Obesity and Diabetes Drug Sales - AInvest
JD Health (06618.HK) has reached a strategic cooperation agreement with Eli Lilly and Co in China. - 富途牛牛
LLY Stock Quote Price and Forecast - CNN
Eli Lilly Partners With China Tech Giant for Obesity Drug Sales - Bloomberg.com
Eli Lilly to offer UK discount on Mounjaro weight-loss jabs - The Independent
Decoding Insider Activity at Eli Lilly: A Closer Look at Recent Share Sales and Buying Conviction - AInvest
Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble - Nasdaq
Eli Lilly CIO Susan Ridlen retiring - Pensions & Investments
Eli Lilly (LLY) technical analysisEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly (LLY) Reports Positive Outcomes for Verzenio in Breast Cancer Trial - uk.finance.yahoo.com
Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals - insights.citeline.com
Stockpiling frenzy prompts Lilly to suspend UK Mounjaro supply - FirstWord Pharma
U-turn on Mounjaro price hike: drug giant scales back planned rise after backlashnew costs revealed in full - Daily Mail
Eshelman Ventures, Eli Lilly back $11M round for RTP firm - The Business Journals
Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears - Benzinga
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro By Reuters - Investing.com
HSBC Upgrades Eli Lilly Amid 'More Sensible' Market Expectations for Weight Loss Pill - MarketScreener
Eli Lilly could bring first widely available GLP‑1 pill for obesity, diabetes to market this year - AOL.com
Stevens Capital Closes Out Position in Eli Lilly - The Motley Fool
Eli Lilly halts UK shipments of Mounjaro diabetes and weight-loss drug - Proactive Investors
Eli Lilly pauses shipments of weight loss drug Mounjaro to UK - The Guardian
Cautious Outlook on Eli Lilly’s Orforglipron Amid Promising Results and Competitive Challenges - TipRanks
Va. backs big pharma deals for AstraZeneca in Albemarle, Eli Lilly in Goochland - RealRadio804
Eli Lilly’s Orforglipron Successfully Completes Third Phase 3 Trial Resulting in Global Regulatory Submissions - PharmExec
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro - uk.finance.yahoo.com
Eli Lilly eyes orforglipron approval after Phase III diabetes trial success - Pharmaceutical Technology
This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Eli Lilly’s Stock (LLY) Is Upgraded by HSBC as Weight-Loss Pill Moves Closer to Approval - TipRanks
Eli Lilly stock rating reiterated at Outperform by BMO on orforglipron data - Investing.com
Eli Lilly stock maintains Buy rating at UBS after positive obesity drug data - Investing.com
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game? - ca.finance.yahoo.com
0.98%
자본화:
|
볼륨(24시간):